TRPV4: new therapeutic target for inflammatory bowel diseases. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Biochemical Pharmacology Year : 2014

TRPV4: new therapeutic target for inflammatory bowel diseases.


The transient receptor potential vanilloid-4 (TRPV4) belongs to a family of ion channels and can be activated by warm temperature, hypotonicity, cell swelling or lipid mediators of the arachidonic cascade. The metabolites or events responsible for TRPV4 activation are associated with inflammation, arguing in favor of a role for this receptor in inflammatory diseases. The first studies have focused their attention on the role of TRPV4 in neurons and endothelial cells but TRPV4 cellular distribution is widespread, particularly in the gastrointestinal tract. Herein, we review a number of studies demonstrating the expression of TRPV4 in the gut, the regulation of its expression and functions by inflammatory mediators in that organ and the consequences of TRPV4 activation or inhibition in the intestine. We further discuss the relevance of considering this receptor as a potential target for therapeutic development in inflammatory bowel diseases.
Fichier principal
Vignette du fichier
BioPharma_2014-TRPV4_and_IBD.pdf (338.25 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-00975985 , version 1 (09-04-2014)



Nathalie Vergnolle. TRPV4: new therapeutic target for inflammatory bowel diseases.. Biochemical Pharmacology, 2014, 89 (2), pp.157-61. ⟨10.1016/j.bcp.2014.01.005⟩. ⟨inserm-00975985⟩
738 View
960 Download



Gmail Facebook Twitter LinkedIn More